Triple agonist peptide for metabolic support and body composition.
Compound_Description
Retatrutide is a novel triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. This innovative peptide represents the next generation of metabolic research compounds, combining the effects of multiple incretin hormones with glucagon receptor activity.
The triple agonist approach offers several potential advantages over single or dual agonists. GLP-1 receptor activation supports glucose metabolism and appetite regulation, GIP receptor activation enhances insulin sensitivity, and glucagon receptor activation increases energy expenditure through enhanced lipolysis and thermogenesis.
Clinical research has shown that Retatrutide can produce significant effects on body composition, with studies demonstrating substantial reductions in body weight and improvements in metabolic parameters. The peptide's multi-receptor approach may provide synergistic effects that exceed those of individual hormone analogs.
Retatrutide is currently being investigated in clinical trials for various metabolic conditions, with early results showing promising outcomes for weight management and metabolic health support.
Research_Applications
- check_circle Metabolic research
- check_circle Body composition studies
- check_circle Incretin hormone research
- check_circle Energy expenditure studies
- check_circle Glucose metabolism research
Scientific_Studies
Retatrutide Phase 2 Trial Results
Jastreboff AM et al. published Phase 2 trial results showing significant weight reduction with Retatrutide.
Triple Agonist Development
Research on the development and mechanism of triple hormone receptor agonists.
Research Use Only
This product is for laboratory research purposes only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.